{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:28:49Z","timestamp":1792510129692,"version":"4.5.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of different endocrine therapies (tamoxifen, aromatase inhibitors, selective estrogen receptor modulators) on bone mineral density (BMD) and fracture risk in postmenopausal breast cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search was conducted in PubMed, Medline, Web of Science, Cochrane Library, and EMBASE databases to identify randomized controlled trials (RCTs). The quality of RCTs was assessed using the Cochrane Risk of Bias Tool, Meta-analysis was performed using RevMan 5.3 software, with primary outcome measures including changes in BMD and fracture risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of five studies involving 20,531 patients were included. Meta-analysis results showed: Osteoporosis incidence: Pooled analysis of two studies yielded pooled odds ratio OR of 0.35 (95% CI: 0.04, 3.00), indicating a slight but non-significant advantage in reducing fracture risk in the experimental group compared to the control group (\n                      <jats:italic>Z<\/jats:italic>\n                      = 0.96,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.34). This finding is based on only two studies, so there is uncertainty associated with it. Heterogeneity was low (I\n                      <jats:sup>2<\/jats:sup>\n                      = 97%). fracture risk: The pooled OR from four studies was 1.40 (95% CI: 1.25, 1.57), demonstrating a statistically significant increase in fracture risk in the experimental group (\n                      <jats:italic>Z<\/jats:italic>\n                      = 5.92,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.001) with low heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      = 29%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The conclusions of this analysis were constrained by the limited number of available studies. Different endocrine therapies might exert varying effects on bone health. Aromatase inhibitors significantly reduce BMD and increase fracture risk, whereas selective estrogen receptor modulators might have a protective effect on bone. These relationships need confirmation in larger studies. Clinicians should consider bone health among other factors when selecting endocrine therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1665389","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:27:21Z","timestamp":1764570441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of different endocrine therapies on bone mineral density and fracture risk in postmenopausal breast cancer patients: a meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Haoran","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1158\/0008-5472.CAN-23-0184","article-title":"Metabolomic rewiring promotes endocrine therapy resistance in breast cancer.","volume":"84","author":"Ahn","year":"2024","journal-title":"Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for Estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III emerald Trial.","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1200\/JCO.23.00455","article-title":"Endocrine therapy for primary and secondary prevention after diagnosis of high-risk breast lesions or preinvasive breast cancer.","volume":"41","author":"Laws","year":"2023","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1158\/1078-0432.CCR-21-3032","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a Phase III Randomized Clinical Trial.","volume":"28","author":"Lu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"102624","DOI":"10.1016\/j.ctrv.2023.102624","article-title":"Estrogen deprivation effects of endocrine therapy in breast cancer patients: incidence, management and outcome.","volume":"120","author":"Cucciniello","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"176424","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer.","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1871530321666210809153152","article-title":"Therapeutic options for the management of aromatase inhibitor- associated bone loss.","volume":"22","author":"Gaudio","year":"2022","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"B10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1007\/s00520-023-07960-8","article-title":"Effect of chemotherapy and different chemotherapy regimens on bone health among Chinese breast cancer women in different menstrual status: a self-control study.","volume":"31","author":"Peng","year":"2023","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","article-title":"Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.","volume":"25","author":"Kaufmann","year":"2007","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1093\/annonc\/mdp033","article-title":"Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.","volume":"20","author":"Rabaglio","year":"2009","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.18.00440","article-title":"Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor-positive breast cancer: long-term follow-up of the BIG 1-98 Trial.","volume":"37","author":"Ruhstaller","year":"2019","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr2837","article-title":"Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.","volume":"13","author":"Regan","year":"2011","journal-title":"Breast Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1089\/jmf.2023.k.0320","article-title":"Supplementation with a probiotic formula having \u03b2-glucuronidase activity modulates serum estrogen levels in healthy peri- and postmenopausal women.","volume":"27","author":"Honda","year":"2024","journal-title":"J Med Food"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine therapy omission in estrogen receptor-low (1%-10%) Early-Stage Breast Cancer.","volume":"43","author":"Choong","year":"2025","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11764-021-00993-0","article-title":"A prospective study of lifestyle factors and bone health in breast cancer patients who received aromatase inhibitors in an integrated healthcare setting.","volume":"17","author":"Kwan","year":"2023","journal-title":"J Cancer Surviv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","article-title":"Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors.","volume":"47","author":"Antonini","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"112431","DOI":"10.1016\/j.exger.2024.112431","article-title":"The effect of tamoxifen on estradiol, SHBG, IGF-1, and CRP in women with breast cancer or at risk of developing breast cancer: a meta-analysis of randomized controlled trials.","volume":"191","author":"Li","year":"2024","journal-title":"Exp Gerontol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/a-2531-9363","article-title":"The Effect of 17\u03b2-estradiol plus norethisterone acetate on estradiol, testosterone, IGF-1 and SHBG in postmenopausal women: a meta-analysis of randomized controlled trials.","volume":"57","author":"Qian","year":"2025","journal-title":"Horm Metab Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jbmr\/zjaf089","article-title":"Estrogen loss activates memory T-cells to compromise bone integrity through distinct cortical compartments in mice.","volume":"40","author":"Wu","year":"2025","journal-title":"J Bone Miner Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jos.2022.07.005","article-title":"Persistent low bone mineral density in adolescent idiopathic scoliosis: a longitudinal study.","volume":"28","author":"Nishida","year":"2023","journal-title":"J Orthop Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","article-title":"The Clinical Effectiveness of Denosumab (Prolia\u00ae) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.","volume":"112","author":"Moshi","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/1078-0432.CCR-23-1248","article-title":"Tamoxifen response at single-cell resolution in estrogen receptor-positive primary human breast tumors.","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12282-024-01595-1","article-title":"Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.","volume":"31","author":"Altundag","year":"2024","journal-title":"Breast Cancer."},{"key":"B27","first-page":"623","article-title":"Addressing unmet need in the management of patients with ER+\/ HER2-, ESR1-mutated metastatic breast cancer: clinician\u2019s perspective.","volume":"21","author":"Rugo","year":"2023","journal-title":"Clin Adv Hematol Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.","volume":"386","year":"2015","journal-title":"Lancet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/ejendo\/lvae111","article-title":"Impact of antiresorptive agents on mortality risk in postmenopausal women with osteoporosis: insights from a nationwide cohort study.","volume":"191","author":"Kim","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1665389\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:27:22Z","timestamp":1764570442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1665389\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":30,"alternative-id":["10.3389\/fmed.2025.1665389"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1665389","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"1665389"}}